- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05889351
Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
A Phase IIa, Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 Compared to Placebo for Nasal Decolonisation of Staphylococcus Aureus.
Study Overview
Status
Detailed Description
Approximately 90 subjects planned screened to achieve 27 randomised and dosed subjects with persistent S. aureus carriage.
On Day 1, subject randomisation in a 2:1 ratio to receive either LTX-109 (n=18) or placebo (n=9). Cohort (1 [8 doses] or 2 [6 doses]) used as a stratification variable to preserve the 2:1 treatment randomisation ratio in each cohort (LTX-109 n=9 or placebo n=5/4).
For all subjects, the IMP was to be applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours). For subjects in Cohort 1, this was followed by 4 additional applications: on Day 1 at 12 hours, on Day 2 at 24 and 36 hours, and on Day 3 at 48 hours. For subjects in Cohort 2 the IMP was likewise applied 4 times during the 4 ½-hour period (on Day 1 at 0, 1 ½, 3 and 4½ hours), but was followed by 2 applications: on Day 1 at 12 hours and on Day 2 at 36 hours. On each dosing occasion, a large drop (approximately 250 μL) of IMP was applied into each nostril and distributed to cover the whole area of the nostril. The subjects were carefully monitored by clinical staff during and after dosing. Safety assessments (AEs, vital signs, safety laboratory assessments and local tolerability) and efficacy assessments (nasal swab) were performed.
All subjects were instructed to wash the body and hair with chlorhexidine body wash and shampoo at the CRU on Day 1 (prior to the first dose) and on Day 2. Subjects were provided with chlorhexidine body wash and shampoo for body and hair wash at home on Day 3, Day 4, Day 5, Day 6 and Day 7. On Day 3 and Day 7, subjects used the chlorhexidine shower before the visits to the CRU.
A final end-of-study visit (Visit 5) took place on Day 7 (+2 days) or after early withdrawal.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Uppsala, Sweden, SE-752 37
- ClinSmart Sweden AB
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing and able to give written informed consent for participation in the study.
- Male or female subject aged 18 to 65 years, inclusive.
- Persistent nasal carrier of S. aureus (MSSA), confirmed by 2 positive bacterial cultures from the nose during the screening period.
- Medically healthy subjects without abnormal clinically significant medical history, physical findings, vital signs, or laboratory values at the time of screening, as judged by the Investigator.
- Women of child bearing potential (WOCBP) had to practice abstinence (only allowed when this was the preferred and usual lifestyle of the subject) or had to agree to use a highly effective method of contraception with a failure rate of < 1% to prevent pregnancy from the date of dosing until 2 weeks after last dose. Female subjects had to refrain from donating eggs from the date of dosing until 3 months after dosing with the IMP. Their male partner had to agree to use a condom from date of first dosing until 2 weeks after last dose if he had not undergone vasectomy.
Male subjects had to be willing to use condom or had to be vasectomised or practice sexual abstinence to prevent pregnancy and drug exposure of a partner and had to refrain from donating sperm from the date of dosing until 3 months after dosing with the IMP. Their female partner of child-bearing potential had to use contraceptive methods with a failure rate of < 1% to prevent pregnancy (see above).
Exclusion Criteria:
- History of any clinically significant disease or disorder which, in the opinion of the Investigator, could either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the administration of IMP.
- Severe eczema or skin wounds, dry or sensitive skin assessed as clinically significant by the Investigator.
- Any positive result at screening for serum hepatitis B surface antigen, hepatitis C antibody and HIV.
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the Investigator, or history of hypersensitivity to drugs with a similar chemical structure or class to LTX-109 or chlorhexidine.
- S. aureus (MSSA and/or MRSA) decolonisation attempt in the 6 months prior to - MRSA positive at screening (Visit 1 and/or Visit 2).
- Inability to take medications nasally.
- Nasal polyps or significant anatomical nasal abnormality, as judged by the Investigator.
- Evidence of open wound, lesion, inflammation, erythema or infection (including active rhinitis, sinusitis or upper respiratory infection or severe acne vulgaris) affecting the nostril area, lip and skin close to the nose.
- History of multiple episodes (>3) of epistaxis within 12 months prior to screening Visit 2.
- Disease in the region of the application sites, significant history of trauma or skin disease in the region of the application sites, current nasal skin or nasal septum condition requiring treatment or nasal surgery in the 6 months prior to screening Visit 2.
- In situ nasal jewellery or open nasal piercings.
- Previous or concurrent treatment with antimicrobials for an infection within the last 28 days prior to the first administration of IMP.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Vehicle treatment
|
Control arm/placebo
|
Active Comparator: Cohort 1
For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours).
For subjects in Cohort 1, this was followed by 4 additional applications: on Day 1 at 12 hours, on Day 2 at 24 and 36 hours, and on Day 3 at 48 hours.
|
Cohort 1 active treatment
|
Active Comparator: Cohort 2
For all subjects, the IMP was applied 4 times during an intensive dosing regimen for 4 ½-hours (on Day 1 at 0, 1 ½, 3 and 4 ½ - hours).
For subjects in Cohort 2 the IMP was likewise applied 4 times during the 4 ½-hour period (on Day 1 at 0, 1 ½, 3 and 4½ hours), but was followed by 2 applications: on Day 1 at 12 hours and on Day 2 at 36 hours.
|
Cohort 2 active treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Operating Window Eradication
Time Frame: 6 hour to 12 hours after start of treatment
|
Number of subjects on LTX-109 versus placebo with bacterial eradication period lasting for 6 hours, from 6 to 12 hours after start of treatment (the "Operation Window").
|
6 hour to 12 hours after start of treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number eradicated at specific timepoints
Time Frame: 4.5 hours, 6 hours, 12 hours
|
Number of subjects on LTX-109 versus placebo with bacterial eradication at 4 ½, 6 and 12 hours after start of treatment.
|
4.5 hours, 6 hours, 12 hours
|
Percentage change in colony forming units (CFUs) in subjects from baseline
Time Frame: 4.5 hours, 6 hours, 12 hours
|
Percentage change in colony forming units (CFUs) in subjects from baseline on LTX-109 versus placebo at 4 ½, 6 and 12 hours after start of treatment.
|
4.5 hours, 6 hours, 12 hours
|
Number of subjects on LTX-109 versus placebo with bacterial eradication period lasting for 48 hours
Time Frame: From 6 hours to 54 hours after start of treatment
|
Number of subjects on LTX-109 versus placebo with bacterial eradication period lasting for 48 hours, from 6 to 54 hours after start of treatment ("48 hours Eradication Window")
|
From 6 hours to 54 hours after start of treatment
|
Adverse events
Time Frame: Through treatment and followup of 7 days
|
Occurrence and frequency of adverse events (AEs)
|
Through treatment and followup of 7 days
|
Local tolerability assessed by health care professional
Time Frame: Pre-dose, 1.5 hours, 4.5 hours, 6 hours, 12, hrs, 54 hours and Day 7
|
Incidence of local reactions (erythema, swelling and lesions) will be assessed.
Each nostril will be evaluated separately and each parameter will be scored using a 4-graded scale (0-3): 0: none,1: mild, 2: moderate, 3: severe
|
Pre-dose, 1.5 hours, 4.5 hours, 6 hours, 12, hrs, 54 hours and Day 7
|
Local tolerability assessed by the subject
Time Frame: Pre-dose, 1.5 hours, 4.5 hours, 6 hours, 12, hrs, 54 hours and Day 7
|
Incidence of local reactions (pruritus and discomfort) will be assessed by the subject.
Each nostril will be evaluated separately using a visual analogue scale (VAS).
|
Pre-dose, 1.5 hours, 4.5 hours, 6 hours, 12, hrs, 54 hours and Day 7
|
Asessment of Vital Signs (Systolic and diastolic blood pressure and pulse)
Time Frame: 24 hours, 54 hours and Day 7
|
Systolic and diastolic blood pressure (BP) and pulse will be measured in supine position after 10 minutes of rest
|
24 hours, 54 hours and Day 7
|
Safety laboratory assessments
Time Frame: 54 hours and Day 7
|
Blood samples for the analysis of clinical chemistry and haematology be collected through venepuncture or an indwelling venous catheter and sent to the certified clinical chemistry laboratory and analysed by routine analytical methods.
Safety laboratory values will be specified and documented as normal, abnormal NCS, or abnormal CS in the eCRF.
Abnormal values assessed by the Investigator as CS will be reported as AEs.
Clinical chemistry parameters to be reported: Alanine aminotransferase (ALT),Albumin, Alkaline, phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin (total and conjugated), Calcium, Creatinine (eGFR included), Glucose, Phosphate, Potassium, Sodium, Urea.
Haematology parameters to be reported: Red blood cell (RBC) count, White blood cell (WBC) count with differential count, Haematocrit (B-EVF), Haemoglobin (Hb), Platelet count.
|
54 hours and Day 7
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Johan Nilsson, MD, Phd, ClinSmart AB
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C22-109-08
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nasal Decolonization of Staphylococcus Aureus
-
Pharma Holdings ASCTC Clinical Trial Consultants ABCompletedA Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of StaphylococcusNasal Decolonization of Staphylococcus AureusSweden
-
Hospices Civils de LyonCompleted
-
Northwestern UniversityCompletedNasal Carriers of Staphylococcus AureusUnited States
-
Centre Hospitalier Universitaire de BesanconUnknownStaphylococcus Aureus Nasal CarriageFrance
-
University Hospital TuebingenNot yet recruiting
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
University of SheffieldRajarata University, Sri LankaUnknown
-
NovaDigm Therapeutics, Inc.Uniformed Services University of the Health Sciences; Infectious Diseases Clinical...CompletedStaphylococcus AureusUnited States
-
Ohio State UniversityCompletedMethicillin-resistant Staphylococcus Aureus | Methicillin-Sensitive Staphylococcus Aureus InfectionUnited States
-
Todd C. Lee MD MPH FIDSANot yet recruitingStaphylococcus Aureus Bacteremia | Staphylococcus Aureus Endocarditis | Staphylococcus Aureus Septicemia | Staphylococcal SepsisCanada
Clinical Trials on Vehicle gel, 4 + 4 applications or 4 + 2 applications
-
Novan, Inc.Completed
-
Novan, Inc.CompletedAcne VulgarisUnited States
-
Novan, Inc.Completed
-
Novan, Inc.Chiltern International Inc.Completed
-
Novan, Inc.Chiltern International Inc.Completed
-
Novan, Inc.CompletedAcne VulgarisDominican Republic, Honduras, Panama
-
Novan, Inc.Premier Research Group plcCompletedMolluscum ContagiosumUnited States
-
UNION therapeuticsCompletedIrritation Potential of Topic AgentUnited States
-
University of UtahNovartisWithdrawnEndometrial CancerUnited States